Skip to content

Study on the application value of contrast-enhanced ultrasound in ischemic retinal diseases

Study on the application value of contrast-enhanced ultrasound in ischemic retinal diseases

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109933
Enrollment
Unknown
Registered
2025-09-26
Start date
2025-10-01
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central retinal artery occlusion

Interventions

Intervention group:Patients meeting the inclusion criteria for CRAO will all receive USMB therapy in combination with standard supportive care.

Sponsors

Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18–70 years, first episode of CRAO, with onset 72h < t <= 14d; 2.Fundoscopy reveals a cherry-red spot, and FFA (fundus fluorescein angiography) shows absence of central retinal artery filling; 3.BCVA (best-corrected visual acuity): Light perception to 20/400, with visual field <=10° (Goldmann perimetry); 4.Patient is conscious, capable of normal communication, and voluntarily provides signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Concurrent uveitis or corneal edema impairing ultrasound transmission. 2. Use of antiplatelet or anticoagulant medications within the past 3 months (requires discontinuation for >=7 days prior to enrollment). 3. Presence of psychiatric disorders or cognitive impairment preventing informed consent or completion of the study protocol. 4. Severe hepatic or renal dysfunction (liver or kidney function parameters exceeding twice the upper limit of normal), uncontrolled hypertension (systolic blood pressure >=180 mmHg and/or diastolic blood pressure >=110 mmHg), or severe diabetic complications (e.g., diabetic nephropathy stage IV, diabetic foot ulcers, etc.). 5. Known hypersensitivity to ultrasound contrast agents or other study-related medications.

Design outcomes

Primary

MeasureTime frame
Visual and Functional Assessment Indicators (Best Corrected Visual Acuity, BCVA; Visual Field Range; Vision-Related Quality of Life Score);Imaging Indicators (Fluorescein Angiography, FFA; Retinal Blood Flow Density, BFD; Retinal Nerve Fiber Layer Thickness, RNFL; Electroretinography, ERG);Biomarker Indicators (Nitric Oxide, NO; Endothelial Nitric Oxide Synthase, eNOS levels in aqueous humor and serum);Vision;

Countries

China

Contacts

Public ContactHe peng

Affiliated Hospital of North Sichuan Medical College

hope18@vip.163.com+86 139 8030 8241

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026